Transforming growth factor-beta activity is potentiated by heparin via dissociation of the transforming growth factor-beta/alpha 2- macroglobulin inactive complex

The control of smooth muscle cell (SMC) proliferation is determined by the combined actions of mitogens, such as platelet-derived growth factor, and the opposing action of growth inhibitory agents, such as heparin and transforming growth factor-beta (TGF-beta). The present studies identify an interaction between heparin and TGF-beta in which heparin potentiates the biological action of TGF-beta. Using a neutralizing antibody to TGF-beta, we observed that the short term antiproliferative effect of heparin depended upon the presence of biologically active TGF-beta. This effect was observed in rat and bovine aortic SMC and in CCL64 cells, but not in human saphenous vein SMC. Binding studies demonstrated that the addition of heparin (100 micrograms/ml) to medium containing 10% plasma-derived serum resulted in a 45% increase in the specific binding of 125I-TGF-beta to cells. Likewise, heparin induced a twofold increase in the growth inhibitory action of TGF-beta at concentrations of TGF-beta near its apparent dissociation constant. Using 125I-labeled TGF-beta, we demonstrated that TGF-beta complexes with the plasma component alpha 2- macroglobulin, but not with fibronectin. Heparin increases the electrophoretic mobility of TGF-beta apparently by freeing TGF-beta from its complex with alpha 2-macroglobulin. Dextran sulfate, another highly charged antiproliferative molecule, but not chondroitin sulfate or dermatan sulfate, similarly modified TGF-beta's mobility. Relatively high, antiproliferative concentrations of heparin (1-100 micrograms/ml) were required to dissociate the TGF-beta/alpha 2-macroglobulin complex. Thus, it appears that the antiproliferative effect of heparin may be partially attributed to its ability to potentiate the biological activity of TGF-beta by dissociating it from alpha 2-macroglobulin, which normally renders it inactive. We suggest that heparin-like agents may be important regulators of TGF-beta's biological activity.

[1]  M J Banda,et al.  Wound macrophages express TGF-alpha and other growth factors in vivo: analysis by mRNA phenotyping. , 1988, Science.

[2]  G. Roodman,et al.  Transforming growth factor beta inhibits formation of osteoclast-like cells in long-term human marrow cultures. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[3]  R. Bizios,et al.  Inhibition of human scleral fibroblast proliferation with heparin. , 1988, Investigative ophthalmology & visual science.

[4]  A. Mauviel,et al.  Transforming growth factor β stimulates collagen and glycosaminoglycan biosynthesis in cultured rabbit articular chondrocytes , 1988 .

[5]  G. Hansson,et al.  Human arterial smooth muscle cells in culture. Effects of platelet-derived growth factor and heparin on growth in vitro. , 1988, Experimental cell research.

[6]  J. Bressler,et al.  Transforming growth factor-β-like activity in tumors of the central nervous system , 1988 .

[7]  K. Miyazono,et al.  Latent high molecular weight complex of transforming growth factor beta 1. Purification from human platelets and structural characterization. , 1988, The Journal of biological chemistry.

[8]  D. Falcone,et al.  Fibronectin Stimulates Macrophage Uptake of Low Density Lipoprotein‐Heparin‐Collagen Complexes , 1988, Arteriosclerosis.

[9]  H. Moses,et al.  Proteolytic activation of latent transforming growth factor-beta from fibroblast-conditioned medium , 1988, The Journal of cell biology.

[10]  O. Katoh,et al.  Effects of platelet derived growth factor, epidermal growth factor and transforming growth factor‐β on the growth of human marrow fibroblasts , 1988, British journal of haematology.

[11]  J. Bergh,et al.  Differential expression of platelet‐derived growth factor and transforming growth factor genes in small‐ and non‐small‐cell human lung carcinoma lines , 1988, International journal of cancer.

[12]  R. Weinberg,et al.  Absence of TGF-beta receptors and growth inhibitory responses in retinoblastoma cells. , 1988, Science.

[13]  G. Spizz,et al.  Decrease in transforming growth factor-beta binding and action during differentiation in muscle cells. , 1988, The Journal of biological chemistry.

[14]  E. Kardami,et al.  Heparin inhibits skeletal muscle growth in vitro. , 1988, Developmental biology.

[15]  J. Wrana,et al.  Differential effects of transforming growth factor-beta on the synthesis of extracellular matrix proteins by normal fetal rat calvarial bone cell populations , 1988, The Journal of cell biology.

[16]  A. Bassols,et al.  Transforming growth factor beta regulates the expression and structure of extracellular matrix chondroitin/dermatan sulfate proteoglycans. , 1988, The Journal of biological chemistry.

[17]  P. Bornstein,et al.  Transforming growth factor beta increases mRNA for matrix proteins both in the presence and in the absence of changes in mRNA stability. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[18]  S. S. Huang,et al.  Human transforming growth factor beta.alpha 2-macroglobulin complex is a latent form of transforming growth factor beta. , 1988, The Journal of biological chemistry.

[19]  T. McCaffrey,et al.  Aging and arteriosclerosis. The increased proliferation of arterial smooth muscle cells isolated from old rats is associated with increased platelet-derived growth factor-like activity , 1988, The Journal of experimental medicine.

[20]  M. Sporn,et al.  Some recent advances in the chemistry and biology of transforming growth factor-beta , 1987, The Journal of cell biology.

[21]  A. Rizzino.  Appearance of high affinity receptors for type beta transforming growth factor during differentiation of murine embryonal carcinoma cells. , 1987, Cancer research.

[22]  L M Wakefield,et al.  Transforming growth factor type beta induces monocyte chemotaxis and growth factor production. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[23]  L M Wakefield,et al.  Distribution and modulation of the cellular receptor for transforming growth factor-beta , 1987, The Journal of cell biology.

[24]  M. Sporn,et al.  Transforming growth factor-beta: selective increase in glycosaminoglycan synthesis by cultures of fibroblasts from patients with progressive systemic sclerosis. , 1987, The Journal of investigative dermatology.

[25]  R. Majack.  Beta-type transforming growth factor specifies organizational behavior in vascular smooth muscle cell cultures , 1987, The Journal of cell biology.

[26]  Gary R. Grotendorst,et al.  TGF-β inhibition of endothelial cell proliferation: Alteration of EGF binding and EGF-induced growth-regulatory (competence) gene expression , 1987, Cell.

[27]  A. Gown,et al.  HHF35, a muscle actin-specific monoclonal antibody. II. Reactivity in normal, reactive, and neoplastic human tissues. , 1987, The American journal of pathology.

[28]  R. Rosenberg,et al.  Antiproliferative effects of heparin on vascular smooth muscle cells are reversed by epidermal growth factor , 1987, Journal of cellular physiology.

[29]  D. Mcclure,et al.  Fibronectin‐associated transforming growth factor , 1987, Journal of cellular physiology.

[30]  R. Rosenberg,et al.  Heparin inhibition of smooth muscle cell proliferation: A cellular site of action , 1986, Journal of cellular physiology.

[31]  S. Schwartz,et al.  Inhibition of endothelial regeneration by type-beta transforming growth factor from platelets. , 1986, Science.

[32]  D. Hill,et al.  Bi‐functional action of transforming growth factor‐β on DNA synthesis in early passage human fetal fibroblasts , 1986, Journal of cellular physiology.

[33]  A. Rizzino,et al.  Preparation and binding of radioactively labeled porcine transforming growth factor type beta. , 1986, Biochemical and biophysical research communications.

[34]  A. Baird,et al.  Inhibition of endothelial cell proliferation by type beta-transforming growth factor: interactions with acidic and basic fibroblast growth factors. , 1986, Biochemical and biophysical research communications.

[35]  H. Moses,et al.  Induction of c-sis mRNA and activity similar to platelet-derived growth factor by transforming growth factor beta: a proposed model for indirect mitogenesis involving autocrine activity. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[36]  M. Bernfield,et al.  Heparin inhibits proliferation of fetal vascular smooth muscle cells in the absence of platelet‐derived growth factor , 1986, Journal of cellular physiology.

[37]  D. Lawrence,et al.  Conversion of a high molecular weight latent β-TGF from chicken embryo fibroblasts into a low molecular weight active β-TGF under acidic conditions , 1985 .

[38]  R. Derynck,et al.  Alpha and beta human transforming growth factors stimulate prostaglandin production and bone resorption in cultured mouse calvaria. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[39]  D. Lawrence,et al.  Further study of β‐tgfs released by virally transformed and non‐transformed cells , 1985, International journal of cancer.

[40]  R. Rosenberg,et al.  An antiproliferative heparan sulfate species produced by postconfluent smooth muscle cells , 1985, The Journal of cell biology.

[41]  Z. Fuks,et al.  Degradation of sulfated proteoglycans in the subendothelial extracellular matrix by human platelet heparitinase. , 1984, The Journal of clinical investigation.

[42]  R. Ross,et al.  The role of endothelial injury and platelet and macrophage interactions in atherosclerosis , 1984, Circulation.

[43]  D. Lawrence,et al.  Normal embryo fibroblasts release transforming growth factors in a latent form , 1984, Journal of cellular physiology.

[44]  E. Levine,et al.  Human endothelial cells: use of heparin in cloning and long-term serial cultivation. , 1983, Science.

[45]  J. Thyberg,et al.  Cell surface components and growth regulation in cultivated arterial smooth muscle cells. , 1983, Journal of cell science.

[46]  C. Heldin,et al.  Demonstration of stimulatory effects of platelet-derived growth factor on cultivated rat arterial smooth muscle cells. Differences between cells from young and adult animals. , 1983, Experimental cell research.

[47]  J. Rowe,et al.  Vascular smooth muscle cell growth kinetics in vivo in aged rats. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[48]  M. Karnovsky,et al.  Inhibition of Rat Arterial Smooth Muscle Cell Proliferation by Heparin: In Vivo Studies with Anticoagulant and Nonanticoagulant Heparin , 1980, Circulation research.

[49]  K. Bentley,et al.  Regulation of cell motility, morphology, and growth by sulfated glycosaminoglycans. , 1986, Cell motility and the cytoskeleton.

[50]  R. Saunders.  Platelets and atherosclerosis. , 1985, Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques.

[51]  M. B. Mathews,et al.  Heparins: varying effects on cell proliferation in vitro and lack of correlation with anticoagulant activity. , 1977, Federation proceedings.